Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

7.3K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
7.3K
Glaucoma: Overview01:25

Glaucoma: Overview

1.0K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.0K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

918
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
918
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

783
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
783
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Three case reports of optic perineuritis complicated by ocular scleritis and hypertrophic pachymeningitis.

Journal of neuroimmunology·2026
Same author

Real-World Treatment Adherence and Persistence with C5 Inhibitor Therapy Versus Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder in Japan.

Neurology and therapy·2026
Same author

Headache prevalence and types in multiple sclerosis and related neuroimmunological diseases: A multicenter study.

Cephalalgia : an international journal of headache·2026
Same author

Outcomes and disease activity during and after pregnancy in Asian women with MOGAD.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Outcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments: A Multicenter Cohort Study.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks: Insights From an International Case Series.

Neurology(R) neuroimmunology & neuroinflammation·2026

Related Experiment Video

Updated: Nov 5, 2025

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

11.7K

[Neuromyelitis Optica Spectrum Disorder].

Tatsuro Misu1

  • 1Department of Neurology, Tohoku University Hospital.

Brain and Nerve = Shinkei Kenkyu No Shinpo
|May 19, 2021
PubMed
Summary

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune condition distinct from multiple sclerosis. New biopharmaceutical therapies offer improved relapse prevention for NMOSD compared to traditional treatments.

Area of Science:

  • Neuroimmunology
  • Autoimmune disorders

Background:

  • Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune condition primarily affecting the optic nerves and spinal cord.
  • It is characterized by antibodies against aquaporin-4 (AQP4), distinguishing it from multiple sclerosis (MS).

Purpose of the Study:

  • To differentiate NMOSD from MS.
  • To discuss diagnostic considerations for NMOSD, including AQP4 antibody testing.
  • To review current and emerging therapeutic strategies for NMOSD relapse prevention.

Main Methods:

  • Review of current literature on NMOSD pathophysiology, diagnosis, and treatment.
  • Comparison of NMOSD with multiple sclerosis.
  • Evaluation of diagnostic assays for aquaporin-4 antibodies.
  • Analysis of treatment outcomes for conventional and novel therapies.

More Related Videos

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

14.3K
Optic Nerve Sheath Point of Care Ultrasound: Image Acquisition
06:09

Optic Nerve Sheath Point of Care Ultrasound: Image Acquisition

Published on: August 18, 2023

2.2K

Related Experiment Videos

Last Updated: Nov 5, 2025

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

11.7K
Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

14.3K
Optic Nerve Sheath Point of Care Ultrasound: Image Acquisition
06:09

Optic Nerve Sheath Point of Care Ultrasound: Image Acquisition

Published on: August 18, 2023

2.2K

Main Results:

  • NMOSD is a distinct humoral immune disease primarily mediated by aquaporin-4 antibodies.
  • High-sensitive cell-based assays for M23-AQP4 antibodies are recommended but require careful interpretation due to potential false results.
  • Disease-modifying drugs for MS may exacerbate NMOSD; conventional treatment involves steroids and immunosuppressants.
  • Biopharmaceutical agents like eculizumab, satralizumab, rituximab, and inebilizumab show promise for NMOSD relapse prevention, potentially surpassing traditional therapies.

Conclusions:

  • NMOSD is a distinct autoimmune disorder from MS, driven by humoral immunity.
  • Accurate diagnosis of NMOSD involves AQP4 antibody testing with awareness of assay limitations.
  • Novel biopharmaceutical therapies represent a significant advancement in managing NMOSD, particularly for aggressive cases, offering superior relapse prevention compared to conventional treatments.